Cardiocast

AHA statement on statin risks, app that diagnoses STEMI, and more


 

This week, the American Heart Association says that statins’ benefits far outweigh the risks, a smartphone app is nearly as good as an ECG at diagnosing STEMI, stroke thrombolysis appears safe in patients prone to GI bleeding, and a new strategy for pausing DOAC therapy works in A-fib patients.

Subscribe to Cardiocast wherever you get your podcasts.
Amazon Alexa
Apple Podcasts

Recommended Reading

NASH drug passes phase 2 trial
MDedge Endocrinology
Risk of cancer in NAFLD is 91% higher than in control subjects
MDedge Endocrinology
Children with poor cardiorespiratory fitness have a higher risk of type 2 diabetes and cardiovascular disease
MDedge Endocrinology
Empagliflozin reduces left ventricular mass
MDedge Endocrinology
‘Phenomenal’ REDUCE-IT establishes triglyceride theory
MDedge Endocrinology
Routine markers predicted histologic response to obeticholic acid in NASH
MDedge Endocrinology
Combined novel risk factors raise coronary event rates
MDedge Endocrinology
Study investigates statin-diabetes link
MDedge Endocrinology
AHA: Statins associated with high degree of safety
MDedge Endocrinology
Obesity meds used by just over half of pediatric obesity programs
MDedge Endocrinology